Sobi announced that experienced commercial leader Holly May has joined the company as vice president of sales and marketing for the United States. May will lead the commercial team in bringing Sobi’s multiple approved medicines to patients in the U.S. She will collaborate with the operations and patient access team to ensure the medicines Sobi provides are optimally accessible to as many appropriate patients as possible. Additionally, she will support the launch of new products in the U.S. derived from Sobi’s pipeline of proprietary medicines or from external sources of innovation. May’s more than 20 years of experience in biopharmaceutical sales and marketing includes previous positions focusing on patients suffering from rare diseases. Most recently she served as vice president and head of U.S. marketing for Fabry disease and lysosomal storage disorders at Sanofi Genzyme, and prior to that she served as vice president and head of the U.S. Fabry disease, responsible for both the commercial activities and teams at Genzyme Corp.